# Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication

> **NCT07537634** · PHASE4 · RECRUITING · sponsor: **Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh** · enrollment: 80 (estimated)

## Conditions studied

- Helicobacter Pylori Infection
- Dyspepsia
- Peptic Ulcer Disease
- Helicobacter Pylori
- H Pylori

## Interventions

- **DRUG:** vonoprazan-based triple therapy (VAL regimen)
- **DRUG:** Esomeprazole-based triple therapy (EAL regimen)

## Key facts

- **NCT ID:** NCT07537634
- **Lead sponsor:** Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2026-08-14
- **Final completion:** 2026-08-14
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07537634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07537634, "Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07537634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*